Tolvaptan OK Would Require Unusual Tolerance Of Drug-Induced Liver Injury
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee briefing docs indicate odds stacked against Otsuka’s tolvaptan kidney disease indication without better efficacy data to counteract drug-induced liver injury risk.